UK markets open in 4 hours 58 minutes
  • NIKKEI 225

    29,392.25
    +60.88 (+0.21%)
     
  • HANG SENG

    28,805.34
    +167.88 (+0.59%)
     
  • CRUDE OIL

    64.83
    +0.12 (+0.19%)
     
  • GOLD FUTURES

    1,814.70
    -1.00 (-0.06%)
     
  • DOW

    34,548.53
    +318.19 (+0.93%)
     
  • BTC-GBP

    40,446.27
    -603.61 (-1.47%)
     
  • CMC Crypto 200

    1,458.51
    -12.91 (-0.88%)
     
  • ^IXIC

    13,632.84
    +50.42 (+0.37%)
     
  • ^FTAS

    4,032.10
    +20.59 (+0.51%)
     

Total number of shares and voting rights in Zealand Pharma at April 30, 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zealand Pharma
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Company announcement – No. 24/ 2021

Total number of shares and voting rights in Zealand Pharma at April 30, 2021

Copenhagen, DK and Boston, MA, April 29, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

In Company announcement No. 19/2021 from April 9, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including April 30, 2021.



Date

Number of shares
(nominal value of DKK 1 each)

Share capital
(nominal value in DKK)

Number of voting rights

April 30, 2021

43,449,842

43,449,842

43,449,842

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com